Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
Sandra P. D’Angelo, James Larkin, Jeffrey A. Sosman, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 2, pp. 226-235
Open Access | Times Cited: 543

Showing 1-25 of 543 citing articles:

Melanoma
Dirk Schadendorf, Alexander C.J. van Akkooi, Carola Berking, et al.
The Lancet (2018) Vol. 392, Iss. 10151, pp. 971-984
Closed Access | Times Cited: 1233
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis
Samra Turajlic, Kevin Litchfield, Hang Xu, et al.
The Lancet Oncology (2017) Vol. 18, Iss. 8, pp. 1009-1021
Open Access | Times Cited: 822
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 822
Immune checkpoint inhibitors in melanoma
Matteo S. Carlino, James Larkin, Georgina V. Long
The Lancet (2021) Vol. 398, Iss. 10304, pp. 1002-1014
Open Access | Times Cited: 818
Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
Candice R. Gurbatri, Ioana Lia, Rosa L. Vincent, et al.
Science Translational Medicine (2020) Vol. 12, Iss. 530
Open Access | Times Cited: 416
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial
Célèste Lebbé, Nicolás Meyer, Laurent Mortier, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 11, pp. 867-875
Open Access | Times Cited: 340
Interleukin-17–induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer
Yu Zhang, Vidhi Chandra, Erick Riquelme, et al.
The Journal of Experimental Medicine (2020) Vol. 217, Iss. 12
Open Access | Times Cited: 319
Cutaneous melanoma
Georgina V. Long, Susan M. Swetter, Alexander M. Menzies, et al.
The Lancet (2023) Vol. 402, Iss. 10400, pp. 485-502
Closed Access | Times Cited: 314
Recent Advances in the Treatment of Melanoma
Brendan D. Curti, Mark B. Faries
New England Journal of Medicine (2021) Vol. 384, Iss. 23, pp. 2229-2240
Closed Access | Times Cited: 300
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Miles C. Andrews, Connie P.M. Duong, Vancheswaran Gopalakrishnan, et al.
Nature Medicine (2021) Vol. 27, Iss. 8, pp. 1432-1441
Open Access | Times Cited: 295
Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets
Felicity Newell, Yan Kong, James S. Wilmott, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 255
Immunotherapy of Melanoma: Facts and Hopes
Sarah A. Weiss, Jedd D. Wolchok, Mario Sznol
Clinical Cancer Research (2019) Vol. 25, Iss. 17, pp. 5191-5201
Open Access | Times Cited: 238
Signal pathways of melanoma and targeted therapy
Weinan Guo, Huina Wang, Chunying Li
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 225
Enterocolitis due to immune checkpoint inhibitors: a systematic review
Émilie Soularue, Patricia Lepage, Jean Frederic Colombel, et al.
Gut (2018) Vol. 67, Iss. 11, pp. 2056-2067
Closed Access | Times Cited: 219
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis
Jun Li, Mercedes A. Duran Paez, Ninjit Dhanota, et al.
Cancer Discovery (2020) Vol. 11, Iss. 5, pp. 1212-1227
Open Access | Times Cited: 214
Age-Specific Incidence of Melanoma in the United States
Kelly G. Paulson, Deepti Gupta, Teresa S. Kim, et al.
JAMA Dermatology (2019) Vol. 156, Iss. 1, pp. 57-57
Open Access | Times Cited: 184
Melanoma subtypes: genomic profiles, prognostic molecular markers and therapeutic possibilities
Roy Rabbie, Peter M. Ferguson, Christian Molina‐Aguilar, et al.
The Journal of Pathology (2018) Vol. 247, Iss. 5, pp. 539-551
Open Access | Times Cited: 183
Melanoma subtypes demonstrate distinct PD-L1 expression profiles
Genevieve J. Kaunitz, Tricia R. Cottrell, Mohammed Lilo, et al.
Laboratory Investigation (2017) Vol. 97, Iss. 9, pp. 1063-1071
Open Access | Times Cited: 180
Inhibitors of immune checkpoints—PD-1, PD-L1, CTLA-4—new opportunities for cancer patients and a new challenge for internists and general practitioners
Marek Z. Wojtukiewicz, Magdalena M. Rek, Kamil Karpowicz, et al.
Cancer and Metastasis Reviews (2021) Vol. 40, Iss. 3, pp. 949-982
Open Access | Times Cited: 168
The mutational landscape of mucosal melanoma
Kelsey W. Nassar, Aik Choon Tan
Seminars in Cancer Biology (2019) Vol. 61, pp. 139-148
Open Access | Times Cited: 153
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial
Xinan Sheng, Xieqiao Yan, Zhihong Chi, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 32, pp. 2987-2999
Open Access | Times Cited: 148
Bacteria and bacterial derivatives as drug carriers for cancer therapy
Zhenping Cao, Jinyao Liu
Journal of Controlled Release (2020) Vol. 326, pp. 396-407
Closed Access | Times Cited: 140
Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial
Bixia Tang, Zhihong Chi, Yingbo Chen, et al.
Clinical Cancer Research (2020) Vol. 26, Iss. 16, pp. 4250-4259
Open Access | Times Cited: 140
Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions
Lili Mao, Zhonghui Qi, Zhang Li, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 114
International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors
Edward C. Kuan, Eric Wang, Nithin D. Adappa, et al.
International Forum of Allergy & Rhinology (2023) Vol. 14, Iss. 2, pp. 149-608
Open Access | Times Cited: 56
Page 1 - Next Page

Scroll to top